Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 361 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ARC Clear all
Completed Not applicable Interventional

A Multicenter Placebo-Controlled Dose Titration Study to Evaluate the Efficacy and Safety of Sandostatin (SMS 201-995) in the Treatment of Patients With Acquired Immunodeficiency Related Diarrhea

NCT00002252
View directory record Official record
Conditions
Diarrhea, HIV Infections
Interventions
Octreotide
Drug
Lead sponsor
Sandoz
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
23
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 9:30 PM EDT
Completed Not applicable Interventional

The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients

NCT00002431
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Chlorhexidine gluconate
Drug
Lead sponsor
Procter and Gamble
Industry
Eligibility
13 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 9:30 PM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of SPC3 in HIV-1 Infected Patients

NCT00002363
View directory record Official record
Conditions
HIV Infections
Interventions
Peptide Construction 3, Synthetic
Drug
Lead sponsor
Columbia Research Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 9:30 PM EDT
Completed Phase 2 Interventional

The Effectiveness of Three Drug Combinations in HIV-Infected Patients Who Have Taken Zidovudine for More Than 12 Weeks

NCT00001063
View directory record Official record
Conditions
HIV Infections
Interventions
Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
31
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 17, 2026, 9:30 PM EDT
Completed Phase 1 Interventional

A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Thalidomide in Subjects With HIV-1 Infection

NCT00000812
View directory record Official record
Conditions
HIV Infections
Interventions
Thalidomide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
6
States / cities
Aurora, Colorado • Minneapolis, Minnesota • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 17, 2026, 9:30 PM EDT
Completed Not applicable Interventional

Open-Label Program of Dideoxycytidine ( ddC ) to Be Used in Combination With Zidovudine ( AZT ) for Treatment of Advanced HIV Disease

NCT00002081
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Zalcitabine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Day and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Wellesley Hills, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 9:30 PM EDT
Completed Not applicable Interventional

Evaluation of the Epidermal Langerhans Cell Population in AIDS / ARC Patients by the Topical Application of a Potent Contact Allergen (1-Chloro-2,4-Dinitro-Chlorobenzene) (DNCB)

NCT00002031
View directory record Official record
Conditions
HIV Infections
Interventions
Dinitrochlorobenzene
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 9:30 PM EDT
Completed Phase 3 Interventional

A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT)

NCT00000751
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
Anti-HIV Immune Serum Globulin (Human), Globulin, Immune, Zidovudine
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
13 Years to 60 Years · Female only
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
48
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2008 · Synced Oct 17, 2026, 9:30 PM EDT
Completed No phase listed Observational

Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons

NCT04401449
View directory record Official record
Conditions
Acute and Long Term Effects of COVID-19 on Systemic Inflammation, Acute and Long Term Effects of COVID-19 on Lung Function, Acute and Long Term Effects of COVID-19 on Cardiac Function, Acute and Long Term Effects of COVID-19 on Kidney Function, Acute and Long Term Effects of COVID-19 on Brain Function
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 17, 2026, 9:30 PM EDT
Completed Not applicable Interventional

A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are Common

NCT00002325
View directory record Official record
Conditions
Mycoses, HIV Infections, Coccidioidomycosis
Interventions
Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Phoenix, Arizona • Tucson, Arizona • Rancho Mirage, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 9:30 PM EDT
Completed Phase 2 Interventional

A Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients

NCT00002150
View directory record Official record
Conditions
HIV Infections
Interventions
Celgosivir hydrochloride
Drug
Lead sponsor
Hoechst Marion Roussel
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
23
States / cities
Mobile, Alabama • Beverly Hills, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 9:30 PM EDT
Completed Not applicable Interventional

3TC (Lamivudine; GR109714X) Open-Label Program

NCT00002108
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine, Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
3 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 9:30 PM EDT
Completed No phase listed Observational

Treatment Study: Reducing Cocaine/Heroin Abuse With SR-Amphetamine and Buprenorphine (ARC)

NCT00698737
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders, Cocaine Abuse or Dependence
Interventions
Not listed
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 22, 2012 · Synced Oct 17, 2026, 9:30 PM EDT
Enrolling by invitation Not applicable Interventional

Radiation Therapy (RT) for Parkinson's Disease (PD)

NCT07218952
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Radiation therapy
Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
45 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 17, 2026, 9:30 PM EDT
Completed Phase 2 Interventional

An Efficacy Study of 2',3'-Dideoxyinosine (ddI) (BMY-40900) Administered Orally Twice Daily to Zidovudine Intolerant Patients With AIDS or AIDS-Related Complex

NCT00000672
View directory record Official record
Conditions
HIV Infections
Interventions
Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
66
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 42 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Oct 17, 2026, 9:30 PM EDT
Completed No phase listed Observational

Clinical Outcomes of 3L+ Therapies Among Patients With Chronic Myeloid Leukemia and Those With T315I Mutation

NCT05611216
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Oct 17, 2026, 9:30 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC

NCT02905591
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, NSCLC
Interventions
Radiation Therapy, Paclitaxel, Carboplatin, Ascorbic Acid
Drug
Lead sponsor
Joseph J. Cullen, MD, FACS
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 17, 2026, 9:30 PM EDT
Terminated Phase 1 Interventional

A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers

NCT04926324
View directory record Official record
Conditions
Rectal Neoplasms, Rectal Neoplasm Malignant
Interventions
Niraparib, Dostarlimab, Short course radiation
Drug · Radiation
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 17, 2026, 9:30 PM EDT
Completed Phase 1 Interventional

A Phase I/II Study of Hyperimmune IVIG in Slowing Progression of Disease in HIV-Infected Children

NCT00000827
View directory record Official record
Conditions
HIV Infections
Interventions
Anti-HIV Immune Serum Globulin (Human)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 12 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
37
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 17, 2026, 9:30 PM EDT
Completed Phase 2 Interventional

A Comparison of Zidovudine Plus Lamivudine Versus ddI Used Alone or in Combination With Zidovudine in HIV-1 Infected Children

NCT00001066
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 15 Years
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
87
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 61 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2011 · Synced Oct 17, 2026, 9:30 PM EDT
Recruiting No phase listed Observational

Feasibility and Usability of a Chest-Strap Ambulatory ECG Monitor in Active Individuals in Comparison With a Traditional Ambulatory ECG Patch Monitor (MoMe ARC)

NCT07772817
View directory record Official record
Conditions
Cardiac Arrhythmia
Interventions
Frontier X Plus chest-strap ECG device, MoMe ARC ambulatory ECG monitor
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
22 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 17, 2026, 9:30 PM EDT
Completed Phase 2 Interventional

Comparison of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (ddC) Versus Ro 31-8959 Plus AZT Plus ddC

NCT00001040
View directory record Official record
Conditions
HIV Infections
Interventions
Saquinavir, Zidovudine, Zalcitabine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
10
States / cities
Birmingham, Alabama • Stanford, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Oct 17, 2026, 9:30 PM EDT
Recruiting Phase 2 Interventional

Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction

NCT07132190
View directory record Official record
Conditions
Brain Metastases, Adult, Brain Tumor - Metastatic, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Extra-cranial Solid Tumors
Interventions
Linear accelerator-based stereotactic radiation for brain metastases using 0mm or 1mm PTV
Radiation
Lead sponsor
Ayal A. Aizer, MD
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 17, 2026, 9:30 PM EDT
Terminated No phase listed Observational

Advancing the Science of Pediatric Interstage Home Monitoring

NCT06547268
View directory record Official record
Conditions
Heart Defects, Congenital
Interventions
Wireless sensor and platform
Device
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Up to 2 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 17, 2026, 9:30 PM EDT